Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Novos forskningsdirektør Martin Lange havde på telefonkonferencen en travl dag på kontoret, hvor næsten halvdelen (8 ud af 20 ...
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...
4d
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This ...
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...
Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and ...
Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on ...
The FTSE 100 index rose 12.01 points, 0.1%, at 8,582.78. The FTSE 250 declined 30.17 points, 0.2%, at 20,623.09. It traded off session lows, however. The AIM All-Share rose 0.72 of a point, 0.1%, at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback